高级检索
孙丽, 丛艳丽, 王晶辉, 李静, 王亚菲, 张富斌, 张振国, 郭玉, 赵新明. 二价脊灰疫苗疑似预防接种异常反应监测分析[J]. 中国公共卫生, 2018, 34(6): 877-881. DOI: 10.11847/zgggws1116674
引用本文: 孙丽, 丛艳丽, 王晶辉, 李静, 王亚菲, 张富斌, 张振国, 郭玉, 赵新明. 二价脊灰疫苗疑似预防接种异常反应监测分析[J]. 中国公共卫生, 2018, 34(6): 877-881. DOI: 10.11847/zgggws1116674
Li SUN, Yan-li CONG, Jing-hui WANG, . Adverse events following immunization of bivalent oral poliovirus vaccines in Hebei province: analysis on surveillance data[J]. Chinese Journal of Public Health, 2018, 34(6): 877-881. DOI: 10.11847/zgggws1116674
Citation: Li SUN, Yan-li CONG, Jing-hui WANG, . Adverse events following immunization of bivalent oral poliovirus vaccines in Hebei province: analysis on surveillance data[J]. Chinese Journal of Public Health, 2018, 34(6): 877-881. DOI: 10.11847/zgggws1116674

二价脊灰疫苗疑似预防接种异常反应监测分析

Adverse events following immunization of bivalent oral poliovirus vaccines in Hebei province: analysis on surveillance data

  • 摘要:
      目的  初步评价河北省Ⅰ型Ⅲ型脊髓灰质炎减毒活疫苗(bOPV)预防接种的安全性。
      方法  收集全国疑似预防接种异常反应(AEFI)监测系统数据,采用描述性流行病学方法进行分析。
      结果  河北省2016年5 — 12月接种bOPV报告的AEFI估算报告发生率为155.97/100万;2015年接种脊髓灰质炎减毒活疫苗(二倍体)(tOPV)AEFI估算报告发生率为88.29/100万,反应类型均以一般反应为主,病例报告主要集中在 ≤ 1岁和第1接种剂次。经统计学分析,接种bOPV AEFI估算报告发生率高于tOPV,其单独接种时发生AEFI的构成比较高,2种疫苗发生AEFI的月龄、剂次和发生时间间隔差异无统计学意义。
      结论  河北省所用bOPV的AEFI估算报告发生率高于国家关于脊髓灰质炎减毒活疫苗的报告发生率,应继续加强AEFI监测,不断完善bOPV的安全性数据。

     

    Abstract:
      Objective  To evaluate the safety of bivalent oral poliovirus vaccine (bOPV) inoculation in Hebei province.
      Methods  We extracted data on adverse events following immunization (AEFI) in Hebei province during 2015 and between May and December 2016 through National Surveillance System for AEFI; then we analyzed the data using descriptive epidemiology methods.
      Results  The reported incidence of AEFI related to bOPV was 155.97 per million inoculations between May and December 2016 and the AEFI incidence related to trivalent oral poliovirus vaccine (tOPV) was 88.29 per million inoculations in 2015 in Hebei province. The reported cases of AEFI were mostly common reactions among small children ≤ one year old and among those receiving their first vaccine inoculation. The estimated AEFI incidence related to bOPV inoculation was significantly higher than that related to tOPV inoculation. A higher proportion of AEFI was observed among the reported cases receiving a single bOPV inoculation. No significant differences were observed in AEFI incidence between bOPV and tOPV among the inoculated children at various month age and with different dose order and in the time interval from the inoculation to the incident of adverse reaction.
      Conclusion  The estimated incidence of bOPV-related AEFI in Hebei province is higher than that in China. Continuous surveillance on bOPV-related AEFI needs to be strengthened.

     

/

返回文章
返回